Obermatt
See Similar Stocks →

Aldeyra Therapeutics

NAQ:ALDX · US01438T1060
BiotechnologySmall

360° View

10
Price/Sales47
Price/Earnings65
Price/Book41
Dividend Yield1
Revenue Growth—
Profit Growth81
Capital Growth10
TSR 52w14
Leverage31
Liquidity43
Refinancing21
Combined7
Analyst Opinions19
Pro Holdings55
Opinion Changes50
Market Pulse59

Profile

CountryUSA
IndustryBiotechnology
SizeSmall
TypePublic Company
ExchangeNASDAQCM
Founded2004
Employees13
Websitealdeyra.com
ISINUS01438T1060
Last UpdateApr 2, 2026
Index & Theme
Infectious DiseasesChronic DiseasesImmunologyOphthalmologyInflammationAllergyRespiratoryPulmonologyBiotechnologyHealth CareTherapeutics

Description

Aldeyra Therapeutics, Inc. is a biotechnology company devoted to discovering innovative therapies designed to treat immune-mediated diseases. The company’s approach is to develop pharmaceuticals that modulate protein systems, instead of directly inh…

Analysis

Aldeyra Therapeutics's 360° View rank of 10 places it among the weakest overall — better than 10% of its true peers.

It's lagging on growth (25) and on the expensive side (43). On safety it is highly leveraged (10), and the market shows muted sentiment (35). Taken together, its Combined rank of 7 reads as among the weakest overall.

360° rank · history

1007550250
10
2026

All-time high

17

Mar 2026

All-time low

10

Jun 2026

Average rank

14

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
47
—
—
—
Price/Earnings
65
—
—
—
Price/Book
41
—
—
—
Dividend Yield
1
—
—
—
Value (overall)
43
—
—
—

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Aldeyra Therapeutics with its peers
Opus Genetics
NAQ:IRD
52
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
MeiraGTx
NSQ:MGTX
18
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Relay Therapeutics
NMQ:RLAY
23
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Jade Biosciences
NAQ:JBIO
—
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Quince Therapeutics
NSQ:QNCX
4
CountryUSA
IndustryBiotechnology
SizeX-Small
Full Stock Analysis →
Zura Bio
NAQ:ZURA
56
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →